复发性急性鼻窦炎患者接受内镜鼻窦手术的健康效用值:一项巢式病例对照研究
该研究纳入20例复发性急性鼻窦炎(RARS)和20例无鼻息肉慢性鼻窦炎(CRSsNP)患者,按年龄和性别1:1匹配,采用SF-6D量表测量健康效用值。RARS组术前0.71±0.14,术后升至0.79±0.13(p=0.031);CRSsNP组术前0.66±0.12,术后升至0.77±0.13(p=0.004);两组术后末次评分及改善幅度均无显著差异。结论认为内镜鼻窦手术可显著改善两组健康效用值至接近常模水平。
要点
- RARS组术前SF-6D健康效用值为0.71±0.14,术后显著改善至0.79±0.13(p=0.031)。
- CRSsNP组术前SF-6D健康效用值为0.66±0.12,术后显著改善至0.77±0.13(p=0.004)。
- 两组术后末次SF-6D评分(p=0.583)及平均改善幅度(0.08±0.16 vs 0.11±0.13;p=0.620)均无显著差异。
核心结论
- RARS和CRSsNP患者经SF-6D测量的健康效用值均存在显著受损,内镜鼻窦手术可显著改善两组健康效用值至接近常模水平。
- 这些数据将有助于未来经济分析和成本效果研究。
研究设计与样本
- 纵向、观察性、前瞻性队列研究,采用巢式病例对照设计,RARS患者(n=20)按年龄和性别1:1匹配CRSsNP对照(n=20),均接受内镜鼻窦手术。
- 健康效用采用医学结局研究简表6D(SF-6D)问卷测量。
主要发现
- RARS组平均随访14.0±6.1个月,CRSsNP组平均随访14.4±5.3个月(p=0.779)。
- 术前平均SF-6D健康效用评分RARS组0.71±0.14 vs CRSsNP组0.66±0.12(p=0.341),两组统计学可比。
- RARS组术后SF-6D评分从0.71±0.14改善至0.79±0.13(p=0.031);CRSsNP组从0.66±0.12改善至0.77±0.13(p=0.004)。
- 两组术后末次SF-6D评分无差异(p=0.583),术后平均改善幅度无差异(RARS组0.08±0.16 vs CRSsNP组0.11±0.13;p=0.620)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Health utility scores quantify an individual's valuation of particular health states and are vital components of health economic studies and cost-effectiveness research. We sought to characterize health utility values for patients with recurrent acute rhinosinusitis (RARS) both before and after endoscopic sinus surgery (ESS), as well as compare health utility to chronic rhinosinusitis without nasal polyposis (CRSsNP). METHODS: Patients with RARS (n = 20) and CRSsNP (n = 20) undergoing ESS were enrolled as part of a longitudinal, observational, prospective cohort. Case patients diagnosed with RARS were age- and gender-matched to controls with CRSsNP using a nested case-control design at a 1:1 ratio. Health utility was measured using the Medical Outcomes Study Short Form-6D (SF-6D) survey. RESULTS: Patients with RARS were followed for an average of 14.0 ± 6.1 (mean ± standard deviation) months compared to an average of 14.4 ± 5.3 months for CRSsNP controls (p = 0.779). Mean preoperative SF-6D health utility scores were statistically comparable between RARS (0.71 ± 0.14) and CRSsNP (0.66 ± 0.12; p = 0.341). Both patients with RARS and CRSsNP reported significant postoperative improvement in SF-6D scores from 0.71 ± 0.14 to 0.79 ± 0.13 (p = 0.031) and from 0.66 ± 0.12 to 0.77 ± 0.13 (p = 0.004), respectively. No difference in last postoperative SF-6D scores were found between RARS and CRSsNP (p = 0.583) or in the average magnitude of postoperative improvement (0.08 ± 0.16 vs 0.11 ± 0.13; p = 0.620). CONCLUSION: Patients with RARS and CRSsNP report significant impairment in health utility as measured by the SF-6D. ESS significantly improves health utility in patients with RARS and CRSsNP to near normative values. These data will help inform future economic analysis and cost-effectiveness research.
引用
- Steele TO, Mace JC, Dedhia R, et al. Health utility values for patients with recurrent acute rhinosinusitis undergoing endoscopic sinus surgery: a nested case control study. Int Forum Allergy Rhinol. 2016. PMID: 27309906. doi:10.1002/alr.21809
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。